Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
PureTech Health ( (GB:PRTC) ) has shared an announcement.
Vor Bio, a company founded by PureTech Health, has entered into an exclusive global license agreement with RemeGen to develop and commercialize telitacicept, a dual-target fusion protein for autoimmune diseases, outside of Greater China. This agreement includes an initial payment of $125 million and potential milestones exceeding $4 billion. Additionally, Vor Bio announced a $175 million private placement to support the development of its clinical pipeline, marking a significant step in its growth strategy and positioning in the autoimmune treatment market.
The most recent analyst rating on (GB:PRTC) stock is a Buy with a £455.00 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.
Spark’s Take on GB:PRTC Stock
According to Spark, TipRanks’ AI Analyst, GB:PRTC is a Neutral.
The stock score reflects significant strengths in earnings call achievements and attractive valuation, despite financial performance challenges and neutral technical indicators. The stock appears undervalued, offering potential upside if operational risks are managed.
To see Spark’s full report on GB:PRTC stock, click here.
More about PureTech Health
PureTech Health is a clinical-stage biotherapeutics company focused on developing treatments for devastating diseases. Its Founded Entity, Vor Bio, is a biotechnology company specializing in the treatment of autoimmune diseases, aiming to advance novel therapies such as telitacicept.
Average Trading Volume: 630,769
Technical Sentiment Signal: Strong Sell
Current Market Cap: £298.8M
See more data about PRTC stock on TipRanks’ Stock Analysis page.